|
|
- 2018
Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesotheliomaDOI: 10.1016/j.ncrna.2018.11.001 Keywords: MicroRNA, Long non-coding RNA, Mesothelioma, Gemcitabine, Pemetrexed, Anticancer drugs AKBA, 3-acetyl-11-keto-β-boswellic acid, Bcl-2, B-cell lymphoma 2, DADS, diallyl sulfide, DHA, docosahexaenoic acid, DIM, 3,3‘-diindolylmethane, DMPM, diffuse malignant peritoneal mesothelioma, EGCG, epigallocatechin-3-gallate, EMT, epithelial-mesenchymal transition, HOTAIR, HOX transcript antisense RNA, RA, retinoic acid, I3C, indole-3-carbinol, MALAT1, metastasis-associated lung adenocarcinoma transcript 1, MPM, malignant pleural mesothelioma, NaB, sodium butyrate, NSCLC, non-small cell lung cancer, PEG, polyethylene glycole, PEITC, phenethylisothiocyanate, PDCD4, programmed cell death 4, PTEN, phosphatase and tensin homolog, SAHA, suberoylanilide hydroxamic acid, SFN, sulforaphane, TSA, trichostatin A Abstract: Gemcitabine and pemetrexed are clinically approved antimetabolites for the therapy of mesothelioma diseases. These drugs are often applied in combination with platinum complexes and other drugs. The activity of antimetabolites depended on the expression levels of certain non-coding RNAs, in particular, of small microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). The development of tumor resistance towards antimetabolites was regulated by non-coding RNAs. An overview of the interplay between gemcitabine/pemetrexed antimetabolites and non-coding RNAs in mesothelioma is provided. Further to this, various non-coding RNA-modulating agents are discussed which displayed positive effects on gemcitabine or pemetrexed treatment of mesothelioma diseases. A detailed knowledge of the connections of non-coding RNAs with antimetabolites will be constructive for the design of improved therapies in future
|
